SRPT Q4 2024 Earnings — Sarepta Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SRPTSarepta Therapeutics, Inc.

$2B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$658M+65.9% YoY

Gross Profit

$526M79.9% margin

Operating Income

$162M24.6% margin

Net Income

$159M24.2% margin

EPS (Diluted)

$1.50

QoQ Revenue Growth

+40.9%

Cash Flow

Operating Cash Flow

$92M

Free Cash Flow

$54M

Stock-Based Comp.

$50M

Balance Sheet

Total Assets

$4.0B

Total Liabilities

$2.4B

Stockholders' Equity

$1.5B

Cash & Equivalents

$1.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$658M	$397M	+65.9%
Gross Profit	$526M	$353M	+49.2%
Operating Income	$162M	$25M	+556.6%
Net Income	$159M	$46M	+248.4%

Geographic Segments

UNITED STATES

$420M85%

Rest of World

$76M15%